December 15 2011

• Have you developed any new research tools?
• Are you inundated with requests for your reagents?
• Interested in generating some additional revenues?

Cancer Research Technology (CRT) has been successfully commercialising research reagents created in academic institutes for over 20 years.

Our track record is built on dedicated, experienced reagent sales personnel, production and distribution facilities and support from in-house marketing, finance and legal teams.

CRT has exclusive rights to commercialise reagents created in programmes funded by Cancer Research UK (CR-UK) and also markets antibodies generated by the University of Birmingham, Leukaemia and Lymphoma Research Immunodiagnostics Unit at the University of Oxford, University College London and University of Newcastle.

CRT is constantly seeking to identify, commercialise and distribute new research reagents.
If you have a reagent for commercialisation, please contact .(JavaScript must be enabled to view this email address).

Benefits of Working with CRT

• Saves time and money as Material Transfer Agreement (MTA) requests are handled by CRT
• Ensures that reagents are widely available to further research programmes across the biomedical spectrum
• CRT has the resources to handle all reagent requests enabling you to focus on your key research objectives
• Generates supplementary revenue streams for originating institutes and host laboratories

The Portfolio
The portfolio currently consists of over 600 monoclonal and polyclonal antibodies, as well as cell lines and transgenic models. A new initiative underway focuses on the commercialisation of small molecules as research tools, of which we have a small yet growing collection. Importantly the research tools represent a diverse range of research interests and are not all oncology-focused.

The vast bulk of CRT’s antibody portfolio is marketed through major worldwide immunochemical suppliers such as BD Biosciences, Life Technologies, Abcam and Millipore, whereas cell lines and transgenics are supplied directly to industrial partners.

Proactive Marketing
CRT produces and widely distributes an Antibody Catalogue and quarterly flyers. Reagents are also promoted through CRT’s website including a fully searchable antibody database with detailed datasheets for every research reagent (antibodies, cell lines, mice and small molecules as tool
compounds): www.cancertechnology.com/tools

Commercialisation
Long-standing relationships with all major worldwide Life Science Reagents companies enable CRT to rapidly commercialise reagents within its portfolio. The reagents business currently maintains hundreds of licensing agreements with over 60 companies.

CRT is wholly owned by the charity Cancer Research UK. All revenues are shared with originating institutes and inventors, and remaining profits are returned to Cancer Research UK to fund further research programmes. Gross revenues, solely for the CRT’s reagent business since 2002 are £13m and for the 2010/11 financial year have exceeded £2m.

See more articles